ARCHIVES

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Tom Hall Names CMMI VP For Clinical Affairs; Rabson, Fauci Names to Institute Of Medicine

June 26, 1987

Natural Substance Blocks Androgen Activity In Vitro

April 27, 2001

John Montgomery Named to Replace Harold Amos On Cancer Panel

April 8, 1983

Director’s Advisory Committee to Make Advice “Kosher”

March 7, 1997

Hopkins, Pennsylvania Ok’d As Comprehensive; No. Remains At 24

May 24, 1991

In Brief: NCI Terminates Straus’ Grant Following Site Visit Report Charging “Lack Of satisfactory Progress

February 19, 1982